SEHK:1672Biotechs
Assessing Ascletis Pharma (SEHK:1672) Valuation After New Obesity And Acne Pipeline Updates
Ascletis Pharma (SEHK:1672) is back on investors’ radar after selecting its first oral amylin receptor peptide agonist, ASC36, for obesity clinical development, alongside new Phase III acne data on denifanstat.
See our latest analysis for Ascletis Pharma.
The recent ASC36 obesity program and acne Phase III readout come on top of a sharp share price move, with a 7 day share price return of 31.04% and a 90 day share price return of 51.95% supporting very large 1 year and multi year total...